Aeglea BioTherapeutics, Inc. (AGLE) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Aeglea BioTherapeutics, Inc. (AGLE) Healthcare & Pipeline Overview

Aeglea BioTherapeutics is a clinical-stage biotech firm specializing in enzyme therapeutics for rare metabolic disorders. Their lead candidate, pegzilarginase, targets Arginase 1 Deficiency and is currently in Phase III trials, positioning them in the niche market of rare disease treatments.

What Is the Investment Thesis for AGLE?

Aeglea BioTherapeutics presents a high-risk, high-reward investment opportunity within the rare disease biotechnology sector. The primary value driver is the successful completion of the Phase III PEACE trial for pegzilarginase in Arginase 1 Deficiency, with potential FDA approval and commercialization by late 2027. Positive trial data could significantly increase the company's market capitalization, currently at $0.05 billion. Further growth will depend on the progress of AGLE-177 in Phase I/II trials for homocystinuria and the advancement of preclinical programs like AGLE-325 for cystinuria. However, the company's negative profit margin of -198.3% highlights the financial risks associated with clinical-stage biotech companies, making it crucial to monitor cash burn and potential future dilution.

Based on FMP financials and quantitative analysis

AGLE Key Highlights

Pegzilarginase is in Phase III PEACE trial evaluating safety and efficacy for Arginase 1 deficiency.

• AGLE-177, a polyethylene glycol modified enzyme, is in Phase I/II clinical trial for homocystinuria.
• Aeglea's preclinical pipeline includes AGLE-325 for the treatment of cystinuria.
• The company has a market capitalization of $48.6M as of May 9, 2026.
• Aeglea BioTherapeutics operates with 69 employees.

Who Are AGLE's Competitors?

AGLE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are AGLE's Key Strengths?

Specialized expertise in enzyme therapeutics.

• Pipeline focused on rare metabolic diseases with unmet needs.
• Lead product candidate in Phase III clinical trial.
• Strong intellectual property portfolio.

What Are AGLE's Weaknesses?

Limited financial resources as a clinical-stage company.

• High dependence on the success of clinical trials.
• Negative profit margin.
• Small number of employees.

What Could Drive AGLE Stock Higher?

Data readout from the Phase III PEACE trial of pegzilarginase for Arginase 1 Deficiency.

• Progress updates on the Phase I/II clinical trial of AGLE-177 for homocystinuria.
• Advancement of preclinical programs, including AGLE-325 for cystinuria.
• Potential for strategic partnerships and collaborations.

What Are the Key Risks for AGLE?

Financial-distress signal — its Altman Z-Score of -0.37 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-31.2%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure to obtain positive results from the Phase III PEACE trial.
• Regulatory delays or rejection of pegzilarginase by the FDA.
• Competition from other companies developing therapies for rare metabolic diseases.
• Dependence on securing additional financing to fund operations.
• Unfavorable safety or efficacy data from clinical trials of AGLE-177.

What Are the Growth Opportunities for AGLE?

• Successful Completion and Commercialization of Pegzilarginase: The successful completion of the Phase III PEACE trial and subsequent FDA approval for pegzilarginase represents a significant growth opportunity for Aeglea. Arginase 1 Deficiency is a rare genetic disorder with limited treatment options, creating a potential market for pegzilarginase. If approved, Aeglea could capture a significant share of this market, driving revenue growth and increasing shareholder value. The timeline for potential commercialization is estimated to be within the next 18-24 months following positive trial results and regulatory approval.
• Advancement of AGLE-177 for Homocystinuria: The ongoing Phase I/II clinical trial for AGLE-177 in homocystinuria presents another growth opportunity. Homocystinuria is another rare metabolic disorder with unmet medical needs. Positive clinical data and subsequent regulatory approval could expand Aeglea's product portfolio and revenue streams. The timeline for potential commercialization of AGLE-177 is estimated to be within the next 3-5 years, contingent on successful clinical trial outcomes.
• Expansion of Preclinical Pipeline: Aeglea's preclinical pipeline, including AGLE-325 for cystinuria, offers long-term growth potential. Cystinuria is a genetic disorder characterized by the formation of cystine stones in the kidneys, and there is a need for more effective treatments. Successful development and commercialization of AGLE-325 could further diversify Aeglea's product offerings and revenue base. The timeline for potential commercialization of AGLE-325 is estimated to be within the next 5-7 years, pending successful preclinical and clinical development.
• Strategic Partnerships and Collaborations: Aeglea can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its therapies. These partnerships could provide access to additional funding, expertise, and resources, enhancing Aeglea's ability to bring its products to market. Potential collaboration opportunities include co-development agreements, licensing deals, and joint ventures.
• Expansion into New Rare Metabolic Diseases: Aeglea can leverage its expertise in enzyme therapeutics to expand its pipeline into new rare metabolic diseases. By identifying new targets and developing novel enzyme-based therapies, Aeglea can further diversify its product portfolio and address unmet medical needs in the rare disease space. This expansion could involve internal research and development efforts, as well as strategic acquisitions of other companies or assets.

What Are AGLE's Competitive Advantages?

• Proprietary enzyme therapeutics platform.
• Patent protection for their product candidates.
• Orphan drug designation for certain therapies, providing market exclusivity.
• Expertise in developing therapies for rare metabolic diseases.

What Does AGLE Do?

Aeglea BioTherapeutics, Inc., founded in 2013 and headquartered in Austin, Texas, is dedicated to developing innovative enzyme therapeutics for individuals suffering from rare metabolic diseases. The company's mission is to address unmet medical needs by designing and developing novel therapies that can significantly improve the lives of patients and their families. Their lead product candidate, pegzilarginase, a recombinant human Arginase 1 enzyme, is currently undergoing a Phase III clinical trial (PEACE trial) to evaluate its safety and efficacy in treating Arginase 1 Deficiency (ARG1-D), a rare genetic disorder that causes elevated levels of arginine in the blood. In addition to pegzilarginase, Aeglea is also developing AGLE-177, a polyethylene glycol (PEG) modified human cystathionine beta-synthase (CBS) enzyme, which is in a Phase I/II clinical trial for the treatment of homocystinuria, another rare metabolic disorder. The company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs focused on identifying and developing new enzyme therapeutics for other rare metabolic diseases. Aeglea BioTherapeutics operates with a team of 69 employees, focusing on research, development, and clinical trials to bring their therapies to market. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC, before changing its name to Aeglea BioTherapeutics, Inc. in March 2015, marking a significant step in its corporate evolution.

What Products and Services Does AGLE Offer?

• Develop human enzyme therapeutics for rare metabolic diseases.
• Design and conduct clinical trials to evaluate the safety and efficacy of their therapies.
• Focus on unmet medical needs in the rare disease space.
• Advance preclinical programs to identify new therapeutic candidates.
• Seek regulatory approvals for their products from agencies like the FDA.
• Potentially commercialize and market approved therapies.

How Does AGLE Make Money?

• Develop and patent novel enzyme therapeutics.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval to market and sell therapies.
• Generate revenue through product sales upon commercialization.

What Industry Does AGLE Operate In?

Aeglea BioTherapeutics operates within the biotechnology industry, specifically focusing on rare metabolic diseases. This sector is characterized by high research and development costs, lengthy regulatory approval processes, and significant market exclusivity upon successful drug development. The market for rare disease treatments is growing, driven by increased awareness, improved diagnostics, and regulatory incentives such as orphan drug designation. Competition includes companies developing therapies for similar metabolic disorders, but Aeglea's enzyme-based approach offers a unique angle. The biotechnology industry is projected to grow at a CAGR of 12% through 2030, offering substantial opportunities for companies with innovative therapies.

Who Are AGLE's Key Customers?

• Patients with rare metabolic diseases, such as Arginase 1 Deficiency and homocystinuria.
• Families of patients with rare metabolic diseases.
• Healthcare providers who treat patients with these conditions.
• Hospitals and medical centers that specialize in rare disease management.

Aeglea BioTherapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.37 places it in the distress zone, a signal of elevated financial risk.

AGLE Valuation & Market Position

With a $48.6M market cap, Aeglea BioTherapeutics, Inc. sits in the micro-cap segment of the market. Relative to its peer group, AGLE's quantitative score of 45/100 is below the peer average of 77/100.

Return on equity for Aeglea BioTherapeutics, Inc. stands at -31.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -23.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.97 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -0.7%, the inverse of the P/E and a quick read on earnings relative to price.

Company Profile

Aeglea BioTherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Austin, US. The company is led by CEO Jonathan D. Alspaugh. AGLE has traded publicly since 2016.

AGLE Financials

AGLE Latest News

No recent news available for AGLE.

AGLE Analyst Consensus

AGLE MoonshotScore

Aeglea BioTherapeutics, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources